# A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy

> **NCT05077137** · PHASE1 · RECRUITING · sponsor: **Duke University** · enrollment: 25 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** Tetanus Diptheria Vaccine
- **BIOLOGICAL:** Polio Boost Immunization

## Key facts

- **NCT ID:** NCT05077137
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-09-07
- **Primary completion:** 2026-09-01
- **Final completion:** 2026-09-01
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05077137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05077137, "A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05077137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*